Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Roche Holding Ltd. : UPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Roche Holding AG and Reminds Investors with Losses to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
07/17/2017 | 10:03pm CET

IRVINE, CA / ACCESSWIRE / July 17, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Roche Holding AG ("Roche Holding" or the "Company") (OTCQX: RHHBY). Investors, who purchased or otherwise acquired shares from March 2, 2017 through June 5, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before the August 7, 2017 lead plaintiff motion deadline.

If you purchased shares of Roche Holding during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

According to the Complaint, throughout the Class Period, Roche Holding issued materially false and misleading statements and/or failed to disclose material information, specifically that the combination of the Company's breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer, and has a higher rate of side effects. Following this news, Roche Holding's stock price dropped materially, causing investors harm according to the Complaint.

If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.


Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474

SOURCE: Khang & Khang LLP

© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
11/23 BioLineRx Reports Third Quarter 2017 Financial Results
11/23 CHUGAI PHARMACEUTICAL : Immune Checkpoint Inhibitor 'Atezolizumab' Significantly..
11/22 CHUGAI PHARMACEUTICAL : Bispecific Antibody Emicizumab Meets Primary Endpoint in..
11/22 ROCHE : Genentech's Hemlibra Significantly Reduced Bleeds in Phase III Study in ..
11/22 ROCHE : Phase III IMpower150 Study Showed Genentech's Tecentriq and Avastin Plus..
11/22 ROCHE : Lung cancer data gives Roches Tecentriq a boost
11/22 ROCHE : announces acquisition of lab technology firm Viewics
11/22 Illumina Wins UK Patent Suit Against Premaitha Health, Ariosa Diagnostics
11/21 ROCHE : Federal Contracts Awarded by Federal Agencies in South Dakota (Nov. 21)
11/21 CHUGAI PHARMACEUTICAL : HEMLIBRA® Receives the World's First Regulatory Approval..
More news
News from SeekingAlpha
11/22 Cabozantinib Franchise Will Continue To Transform Exelixis' Fortunes In 2018
11/22 3 THINGS IN BIOTECH YOU SHOULD LEARN : November 22, 2017
11/21 YOUR DAILY PHARMA SCOOP : Roche Rallies, Alnylam Granted BTD, Celsion Soars
11/21 3 THINGS IN BIOTECH YOU SHOULD LEARN : November 21, 2017
11/20 Roche Rocks On With More Good News
Financials ( CHF)
Sales 2017 53 402 M
EBIT 2017 18 161 M
Net income 2017 11 138 M
Debt 2017 10 106 M
Yield 2017 3,49%
P/E ratio 2017 18,39
P/E ratio 2018 16,89
EV / Sales 2017 4,18x
EV / Sales 2018 3,95x
Capitalization 213 B
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 274  CHF
Spread / Average Target 11%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.6.15%216 979
JOHNSON & JOHNSON19.17%368 832
NOVARTIS12.82%222 846
PFIZER9.08%211 188
MERCK AND COMPANY-7.64%148 286
AMGEN16.24%123 376